

Cover Story
Relying largely on maturing data from the European trials of screening for prostate cancer, the U.S. Preventive Services Task Force has given a better grade—a “C”—to screening for prostate cancer.
By Matthew Bin Han Ong
In Brief
Funding Opportunities
Clinical Roundup
Drugs & Targets
Trending Stories
- Joe Fraumeni, founder of molecular epidemiology, dies at 93
“It’s hard to imagine a world without the presence of this gentle scientific giant.” - The Directors: Directors of two Midwestern cancer centers tell us about the challenging healthcare economics in rural areas
“Institutions are feeling crunched in so many different directions” - Robert Mayer tells us about pancreatic cancer’s hopeless past as new data shows promise
- Dana-Farber names its under-construction freestanding hospital: the Lavine Bekenstein Cancer Hospital
- To keep the early clinical trial enterprise in the U.S., HHS pledges to simplify regulatory requirements
- FDA advisory panel recommends first-of-its-kind mRNA flu vaccine for older adults




















